flow trial semaglutide kidney outcomes 2024 results Study: slowed progression of CKD, cut cardiovascular events, mortality risk The FLOW trial for semaglutide – flow semaglutide Results from this

Both had a similar average weight loss at the end of the trial (14.9% for Wegovy vs 15% for Mounjaro), and both had a similar amount of participants who achieved at least a 5% decrease in body weight (86.4% for Wegovy vs 85% for Mounjaro)

doi: 10.1158/1940-6207.CAPR-13-0424 238 VancuraABuPBhagwatMZengJVancurovaI

Some doctors believe the demand for Mounjaro soon could surpass other weight-loss injectables

In the first 5 months of 2025, there were 1,392 prescriptions filled at the specialty pharmacy

Sato-Ueshima M

Apply to alleviate chemotherapy, radiation therapy, especially the toxic effects of high-dose chemotherapy or for the treatment of all kinds of hypoxemia, such as acute anemia, acute respiratory distress syndrome, sepsis, etc